Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2007

Coley Receives $3M from GSK with Start of Phase III NSCLC Study

  • Coley Pharmaceutical obtained a $3 million milestone payment from GlaxoSmithKline (GSK). The payment is associated with GSK’s initiation of its Phase III trial in non-small-cell lung cancer (NSCLC) investigating an immunotherapeutic cancer vaccine containing Coley’s VaxImmune™ vaccine adjuvant.

    In June 2007, GSK began a Phase III trial in lung cancer to evaluate MAGE-A3 antigen-specific cancer immunotherapeutic (MAGE-A3 ASCI) in patients with early-stage, completely resected NSCLC. VaxImmune is one of the components of MAGE-A3 ASCI, intended to increase an antitumor immune response.

    VaxImmune is Coley’s TLR9 agonist designed to induce both an enhanced antibody response and a potent killer T-cell immune response when used in conjunction with vaccines to achieve and sustain a clinical response without compromising safety. Coley has granted GSK worldwide licenses for the use of VaxImmune in the development of vaccines for certain cancers and infectious diseases.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »